Neuralstem, Inc. “Right to Try”admin
By Market Exclusive ACCESSWIRE / Mar 3, 2014 / Neuralstem, Inc. (NYSE MKT: CUR) published a blog post on the Company’s website (http://neuralstem.com/neuralstem-ceo-blog/208-every-man-gotta-right-to-decide-his-own-destiny) which was republished on TheChairmansBlog.com. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
In his new blog, President and CEO Richard Garr writes about the Right to Try bill progressing through Arizona State Legislature. He writes, “At Neuralstem we are keeping a sharp eye on this legislation. As we move into the final stretch of transplantations for our Phase II therapy for ALS…we are keenly aware of all of the patients who cannot be included in the trial.”
Neuralstem’s patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. Neuralstem.com
In addition to ALS, the Company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The Company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.
Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions. The Company has completed a Phase I safety trial evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD). Additional indications might include traumatic brain injury (TBI), Alzheimer’s disease, and post-traumatic stress disorder (PTSD). Neuralstem.com
TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information. http://www.thechairmansblog.com/
Posted: March 3rd, 2014 under ACCESSWIRE.